OV101

DRUG2 trials

Sponsors

Healx AI

Conditions

Angelman SyndromeFragile X Syndrome

Phase 1

Single Dose Pharmacokinetic (PK) Study

CompletedNCT03109756

Healx AIAngelman Syndrome, Fragile X Syndrome

Start: 2017-04-03End: 2017-11-28Updated: 2017-11-30

Phase 3

An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome

TerminatedNCT03882918

Healx AIAngelman Syndrome

Start: 2019-01-31End: 2021-06-30Updated: 2025-07-18